Literature DB >> 15024746

CYLD mutation causes multiple familial trichoepithelioma in three Chinese families.

Guangyong Zheng1, Landian Hu, Wei Huang, Kaide Chen, Xuejun Zhang, Sen Yang, Jianfang Sun, Yiqun Jiang, Guangbin Luo, Xiangyin Kong.   

Abstract

Multiple familial trichoepithelioma (MFT) and familial cylindromatosis are two clinically distinct cancer syndromes. MFT patients developed mostly trichoepithelioma in the face while cylindromatosis patients developed cylindromas predominantly (approximately 90%) on the head and neck. However, multiple familial trichoepithelioma is occasionally associated with familial cylindromatosis while cylindromatosis patients can also develop trichoepithelioma. This has led to the speculation that the 2 types of dermatoses may be caused by dysfunction of a common pathway. Previously, a candidate MTF locus has been mapped to 9p21 while disease gene for familial cylindromatosis, the CYLD gene located on 16q21-13 has been identified. Here, we show that mutations in the CYLD gene are also the genetic basis for three different Chinese families with MFT. Sequence analysis reveal a single nucleotide deletion, c.1462delA (P.Ile488fsX9) in exon 9, a nonsense mutation, c.2128C>T (p. Gln710X) in exon 17, and a missense mutation, c.2822A>T (p. Asp941Val) in exon 21 in each of the three families respectively. This provides direct evidence that the mutations in CYLD can cause two clinically distinct cancer syndromes. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024746     DOI: 10.1002/humu.9231

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.

Authors:  Atsushi Uematsu; Kohki Kido; Hirotaka Takahashi; Chikako Takahashi; Yuta Yanagihara; Noritaka Saeki; Shuhei Yoshida; Masashi Maekawa; Mamoru Honda; Tsutomu Kai; Kouhei Shimizu; Shigeki Higashiyama; Yuuki Imai; Fuminori Tokunaga; Tatsuya Sawasaki
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

Review 2.  Skin adnexal neoplasms--part 1: an approach to tumours of the pilosebaceous unit.

Authors:  K O Alsaad; N A Obaidat; D Ghazarian
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

Review 3.  Analysis of phenotype-genotype connection: the story of dissecting disease pathogenesis in genomic era in China, and beyond.

Authors:  Yan Shen; Qi Xu; Zeguang Han; Han Liu; Guang-Biao Zhou
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

Review 4.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

5.  CYLD Promotes TNF-α-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells.

Authors:  Xing Lin; Qianshun Chen; Chen Huang; Xunyu Xu
Journal:  Mediators Inflamm       Date:  2016-09-25       Impact factor: 4.711

6.  Multiple familial trichoepithelioma: confirmation via dermoscopy.

Authors:  Cristián Navarrete-Dechent; Shirin Bajaj; Ashfaq A Marghoob; Sergio González; Daniel Muñoz
Journal:  Dermatol Pract Concept       Date:  2016-07-31

7.  Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.

Authors:  Neil Rajan; James A A Langtry; Alan Ashworth; Catherine Roberts; Pam Chapman; John Burn; Alison H Trainer
Journal:  Arch Dermatol       Date:  2009-11

8.  Trichoepithelioma: a rare but crucial dermatologic issue.

Authors:  Ali Akbar Mohammadi; Seyed Morteza Seyed Jafari
Journal:  World J Plast Surg       Date:  2014-07

9.  Twelve Years' Observation of Multiple Familial Trichoepithelioma with Squamous Carcinoma.

Authors:  Huifu Ma; Song Feng; Wenjun Pei; Feng Jin
Journal:  Indian J Dermatol       Date:  2016 May-Jun       Impact factor: 1.494

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.